Quick Answer
Amneal Pharmaceuticals, Inc. reported Stockholders Equity of -$70.79 million for the year ending 2025.
- Amneal Pharmaceuticals, Inc. showed an increase of +35.2% in Stockholders Equity from 2024 to 2025.
- This data is from Amneal Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2017 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: $0.00 | Q1 2018: $0.00 | Q2 2018: $494.50 million | Q3 2018: $501.11 million | Q1 2019: $472.21 million | Q2 2019: $459.66 million | Q3 2019: $218.00 million | Q1 2020: $318.38 million | Q2 2020: $306.00 million | Q3 2020: $301.04 million | Q1 2021: $323.02 million | Q2 2021: $346.11 million | Q3 2021: $350.51 million | Q1 2022: $391.13 million | Q2 2022: $280.33 million | Q3 2022: $297.47 million | Q1 2023: $294.41 million | Q2 2023: $318.17 million | Q3 2023: $330.86 million | Q1 2024: -$63.72 million | Q2 2024: -$57.47 million | Q3 2024: -$93.43 million | Q1 2025: -$131.67 million | Q2 2025: -$112.12 million | Q3 2025: -$109.46 million.
- Historical annual values: Fiscal year 2025: -$70.79 million | Fiscal year 2024: -$109.27 million | Fiscal year 2023: $19.78 million | Fiscal year 2022: $298.42 million | Fiscal year 2021: $360.34 million | Fiscal year 2020: $303.27 million | Fiscal year 2019: $232.01 million | Fiscal year 2018: $504.75 million | Fiscal year 2017: $0.00 | Fiscal year 2017: $0.00.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: